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Abstract 
 
Botulinum toxin is widely used in facial rhytide treatments. The duration of its 
effect’s influences treatment intervals, cost and convenience to the patient. These 
are key factors in successful aesthetic procedures. A review of the literature 
found that duration of effect was between 2 and 6 months, with most 
experiencing loss of maximal contraction for 3-4 months. Treatments may last 
between 3-4 months, and occasionally up to 6 months. No specific definition of 
effectiveness/ efficacy has been described and used to measure comparable end 
points. Additional research should help clarify the impact of brand, age, gender, 
ethnicity, repetition of treatment and zinc-phytase supplementation.  
 
Clinical Relevance  
 
The aim of this review article was to ascertain the duration of action of 
Botulinum toxin type A in the treatment of glabellar frown lines 1 in order to 
provide evidence based advice to patients by ascertaining the average length of 
time a patient perceives their aesthetic botulinum toxin treatment lasts, and 
compare that to the published values.  
  
Background  
 
The neurotoxin produced by the bacterium Clostridium botulinum, Botulinum 
toxin, was first identified in 1897. 2 It can produce muscle weakness or paralysis 
that has been exploited for treatments of muscle hyperactivity. It was first used 
by Dr. Alan Scott to treat strabismus 3 and subsequently prescribed for the 
treatment of muscle spasms in many other areas of the body. Scott 
concomitantly predicted other potential future applications, including a role in 
providing cosmetic enhancement.  
 
The purified crystallised toxin serotype A (specifically BotoxTM) was initially 
given FDA approval in 1989 for the treatment of involuntary muscle disorders 
such as strabismus. 2 In 1993 Blitzer et al. described the use of the toxin for the 
management of ‘hyper-functional lines of the face’; a cosmetic use was thus 
born4. The latter worked by impeding the underlying muscle contraction causing 
relaxation and thus flattening of the overlying skin. Since then, its use in the 
treatment of rhytides (wrinkles) has spread considerably, with the global market 
forecast to hit $2.9 billion by 2018 according to Global Industry Analysts Inc. 6 
Indeed there has been a very large rise, with a spiralling increase in the number 
of patients seeking aesthetics treatments, with the market growing 6% in 1 year 
alone. 7 A study by the UK Department of Health in 2013 estimated that 75% of  
the cosmetic market value in the UK is accounted for by Botulinum Toxin A and 
other non-surgical procedures. 8  
 
Owing to the dental origin of such aesthetic changes, the dental surgeon is ideally 
placed to diagnose and treat facial concerns; hence there is a great overlap in 
these fields. As the dentist is trained in head and neck anatomy, and performs 
injections regularly as part of their routine work it may follow that this 
procedure should become part of their practice.  There are several well accepted 
techniques using Botulinum toxin around the oral cavity, such as treatment of 
the ‘gummy-smile’ or ‘smokers lines’ in the upper lip. These are currently off-
label uses for the toxin, and as such studies and clinical data are comparatively 
scarce. It is for this reason that this review focuses on the better studied, on-
label, treatment of the glabellar region in order to achieve some homogeneity of 
studies compared.  
 
In the UK, only three preparations of Botulinum Neurotoxin type A are licensed 
for the treatment of glabellar lines; OnabotulinumtoxinA (Botox/Vistabel, 
Allergan), IncobotuliunumtoxinA (Bocouture/Xeomin, Merz) and 
AbobotulinumtoxinA (Azzalure/Dysport, Ipsen.).9  
 
The Pharmacological Effects of Botulinum Toxin  
 
Neuromuscular transmission is usually achieved when the neurotransmitter 
acetylcholine is transported to presynaptic terminals (the nerve endings) in 
membrane vesicles which fuse with the cytoplasmic membrane leading to 
release of the neurotransmitter into the neuromuscular junction. (This is the 
process which administration of Botulinum toxin blocks.) From here it diffuses 
across the synaptic gap to bind with the nicotinic cholinergic receptors on the 
postsynaptic membrane of the muscle surface.10 The effect of preventing 
neurotransmission at motor nerve endings is to temporarily denervate and 
hence relax the muscles local to the injection site.4  
 
It is not yet known how the toxin is metabolised or otherwise eliminated from 
nerve endings.11 Indeed, there remain some considerable gaps in our knowledge 
of the mechanism for absorption, distribution, metabolism and elimination of the 
toxin.12 However, it has been postulated that the toxin binds irreversibly to the 
synaptic nerve endings, and is then metabolised over the proceeding months. It 
is likely that the protein degrades and is removed by the body and the 
pharmacological effects then ceases.  
 
There is no evidence of muscular atrophy following repeated Botulinum toxin 
injections over long periods of time, but there have been incidences of resistance 
by antibody development. Certainly, with Botulinum toxin treatments being so 
common, it follows that with greater numbers of treatments the number of 
incidents of immunity should rise. The latter has been reported to be rare; 
Kawashima and Harii found no incidence of antibody formation when testing the 
363 subjects of their 2009 study. 13 There is also no evidence of hypersensitivity 
developing. However, potential behavioural modification whereby the patient 
learns to avoid ‘undesirable’ facial movements may occur. 4 
  
  
Applications in Medical Dystonias and Aesthetics  
Strabismus and other ocular motility applications  
Focal cervical  
Oromandibular and laryngeal dystonias  
Blepharospasm (focal dystonia of the orbicularis oculi)  
Spasticity relating to Multiple Sclerosis and other neurological conditions  
Tennis elbow and other muscular pains  
Bell’s Palsy  
Hyperhidrosis  
Chronic migraines (FDA approval 2010)  
Over active bladders (approved in 2011).  
Glabellar rhytides  
Figure 1: Different applications for Botulinum toxin A (1,14).  
 
The therapeutic scope of the Toxin is quite varied (Figure 1) Botulinum toxin has 
been used cosmetically since its cosmetic effects were documented in 1989. In 
facial aesthetic treatments, the toxin works by causing weakening of the 
underlying muscle which exhibits habitual contraction, causing relaxation and 
thus flattening of the overlying skin. 4 The use of Botulinum toxin for treatment  
of facial rhytides is ‘off-label’ (an unlicensed, but well accepted use) aside from 
glabellar lines and thus should be explained to the patient at point of consent.4  
  
How the effects may be determined as ongoing  
 
For ongoing effects to be assessed and measured, it is important to clarify what 
constitutes ‘effective’. This is a very difficult question as the degree of effect 
varies, and the methods of assessing and measuring it are diverse.  
 
Electromyographic (EMG) Guidance has been documented as an aid to locate 
where to inject the toxin. Although ‘in neurologic indications EMG represents the 
gold standard for detection of muscular activity, the spatial resolution of this 
method probably limits its usefulness in aesthetic applications.’15 Studies have 
used a scoring system such as the Facial Wrinkle Score in order to assess the 
effect of toxin therapy. These are very subjective criteria and may vary between 
different assessors, and a disadvantage is they are subject to body dysmorphia if 
self-assessment is used.  
 
Bhatnagar and co-workers16 have described the ‘digital image speckle 
correlation’ whereby skin detail such as the pores of the skin are used to map 
changes in skin surface overlying the muscles and thus ‘track the degree of 
contraction’ and associated skin displacement.  
 
None of the methods investigated for measuring or quantifying longevity gives a 
good standard, as there is no consensus on what is ‘effective’, nor a quantifiable, 
reproducible method by which to measure it. Only once ‘effective’ is defined, can 
duration be assessed.  
The patients’ perceived outcomes are hugely important as this is what will 
contribute to patient satisfaction and as a result either repeat business or 
conversely, complaints. It is however, subjective, and there may be many factors 
which influence the patients’ self reporting.17, 18, 19 As these elective treatments 
have a cosmetic, rather than a therapeutic value, the psychological health of a 
patient will hugely influence their perceived success as patients with Body 
Dysmorphic Disorder do not typically benefit from cosmetic procedures20. 
 
Among the studies included there were 7 very different methods for assessing 
effective duration;  
1 Patient perceived duration  
2 Investigator-assessed wrinkle severity (by various subjective scales; FWS, 
GLSS)P 
3 Patient self assessed wrinkle severity (as above) 
4 Skin movement at maximal contraction 
5 Improvement at repose 
6 Length/depth of rhytide at maximal contraction compared to  
baseline 
7 Treatment intervals 21  
  
Ascher et al.21 used the time between first and second injection as their measure 
of duration. Repeat treatment intervals may be used to gauge how long a patient 
feels the treatment lasted satisfactorily. However, there are other factors; 
availability of clinics, cost of treatments, social factors around access to 
treatment such as time, distance, perceived healing time. The choice of outcome 
measures differs greatly; quantitative DISC, and the more subjective assessment 
by both the plastic surgeon and the patient showed a clear correlation. However, 
the reappearance of muscle contraction (DISC) preceded the wrinkle appearance 
for patients by 4-8 weeks, demonstrating that potentially the wrong measure 
was employed.17  
 
Eight of the studies used patient assessment as at least one measure. This is 
relevant in a clinical setting, as the patients perceived benefit would be a huge 
influencer on their satisfaction and potential repeat business. It is however 
fraught with potential bias where the patient is aware of the desired outcome 
and also potentially the influence of cost and access where treatment intervals 
are concerned.  
 
Dailey et al.22 used patient photographs, which limited their population to lighter 
skin tones in order to be able to clearly image the rhytides. This variation in 
method obviously produces results that cannot be compared, that in the main-
part measure something that although measurable, or subjectively quantifiable, 
is in truth not the effect that should be being considered for aesthetic purposes.  
The durations of effects have been simplified by averaging out where possible, 
but it is important to note that in many cases the duration was deemed to go 
beyond the length of the study and as such these studies are a guide that effects 
are on-going, but not a measure of the actual longevity.  
 
It does not appear that there is an obvious pattern in assessment method and 
duration. Certainly, the patient perceived endpoint, which is weaker in terms of 
evidence has a shorter duration, so it may suggest that the longer durations are a 
better indicator.  
A
 
B
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Figure 2: Photographs to show glabellar frown lines a) at rest and b) at full 
contraction, then c) 2 weeks following treatment with Botulinum toxin. 
 
Factors that can affect the longevity of Botulinum toxin treatment?  
 
There are many variables in treatments with Botulinum toxin, both in the 
manner in which it is administered, and also the subject in which it is injected. If 
we know their effect, we may optimise results and give better advice.  
 
Dose of toxin used, and its effect on longevity.  
 
Reduced dosages may result in unacceptably short durations.23 Whilst a higher 
dose may be found to last longer, this must be weighed against higher doses 
potentially spreading to adjacent muscles with potentially adverse effects, and 
also the increased cost to the patient.  
 
A study by Hankins et al.24 found there to be no significant difference in the 
longevity of effects from injection doses of 4-10 U per site. Moreover, lower 
volumes used at a higher concentration were reported to be less uncomfortable, 
should have less spread, and thus be less likely to affect areas beyond the 
intended site.  
Studies which test doses lower than recommended in the product information 
may be useful, as this may be common in practice, as they would be cheaper, and 
could also explain some poor treatment durations, and justify why clinicians 
should use the recommended doses.  
 
Dose may not actually be comparable between products, and needs further 
investigation. Although there are conversions suggested between Speywood 
units, these vary in the literature, and may vary in different applications.  
 
Where the durations are shown in order of dose, there is no clear pattern to 
suggest a good correlation. The doses are, however, mainly similar, and there are 
many other variables in the study designs. In addition, the doses are often 
altered to reflect for example the muscle mass, so higher doses may be being 
used in larger muscles.  
 
Previous studies by Caruthers and co-workers25 and Lowe and co-workers 26 
reported that higher doses are more efficacious for longer in the applications 
they studied. This result was corroborated by Harii and Kawashima (2008) 27 
who found the mean duration rose from 7.9 weeks for 10U to 9.4 weeks for 20U. 
The study by Grimes et al. (2009)28 however suggests that 30U is no more 
effective than 20U in this small sample, so there may be an optimal dose. In fact 
Kane et al.29 found that as the dose increased, the percentage of responders 
decreased. However, it was suggested this was because those given larger doses 
were those with a greater muscle mass, and therefore were likely to be worse 
responders, so that this result was not directly related to the dose given. This 
would potentially impact on the gender results, as men tend to have greater 
muscle mass than women.  
 
Licensed doses limit the study of the effect of dose on longevity, and so it is 
sensible that future research should include this in the study.  
 
Location  
 
Area of treatment may impact treatment efficacy and duration. In a study by 
Blitzer et al. better results were found in the forehead than glabellar region 
(Figure 2), however, this study concentrates on the glabellar alone.  
 
 Figure 3: Photograph of Botulinum toxin being administered to the glabellar 
region.  
 
Number of injection sites  
 
Figure 3 (below) shows that most of the studies employed 5 injections sites (1 
mid-line in the procerus, and 2 each side in the glabellar (see figure 2 above), in 
slightly different positions in some American studies) and there was no evidence 
to suggest the number of sites influences duration.  
 
Intervention Outcome 
Study 
Type of toxin 
(AbobotulinumtoxinA = A, 
IncobotulinumtoxinA = I, 
OnabotulinumtoxinA = O) 
Total 
Glabellar 
Dose/(no. 
injection) 
Duration (days)  
Kassir, 2013 
30 
A, O 
8U Ona, 20 
Speywood 
Units Abo 
27% 150 A, 2% 
150 O  
Harii and 
Kawashima, 
2008 27 
O 10-20U/(5) 
65.8 (20U) 55.3 
(10U)  
Jandhyala, 
2015 9 
A, I, O NR 
A- 111, I-125, O-
108  
Banegas et al., 
2013 31 
O, I 
Mean 15.2U-
O, 15.3U-I 
O- 180, I-144  
Kane et al., A 50-80 92.8  
2009 29 Speywood 
Units 
Grimes and 
Shabazz, 2009 
32 
O 20-30U/(5) 80-90% 120+  
Lowe et al., 
1996 26 
O 20U/(2) 124.6  
Dailey et al., 
2011 22 
O 20U/(5) 42% 168+  
Imhof, 2011 
33 
I 20U/(5) 80% 84+  
Prager et al., 
2013 34 
I 25U/(5) 75% 150+  
Proebstle et 
al., 2014 35 
I 30U/(6) 
168+ (1/2 unit 
improvement)  
Moy et al., 
2009 36 
A 50U/(5) 88  
Figure 4 shows mean durations in each study relative to dose used. Toxin type 
also shown.  
  
Supplements  
 
It has been found that zinc is required in the action of the light (50kDa) chain. 
During translocation into the cytoplasm the light chain is denatured and the 
chelation site loses zinc, then having to regain another zinc from the cytosols 
ambient pool.37 As a result recent studies suggesting zinc may have an effect on 
the action of the toxin binding and hence potentially implications on longevity. 
There was no mention of zinc as a variable in any of the papers reviewed, 
however, recent widespread press coverage26 has created interest from patients 
who wish to know if the addition of zinc is a viable method of increasing 
treatment longevity. According to the study by Koshy et al. (2012) 38 92% of 
participants who received supplementary dietary zinc in combination with 
Phytase supplements (phytase is believed to improve zinc absorption) had an 
increase in longevity. The level of evidence however, is still poor as the patient 
sample receiving the zinc- phytase supplement marketed as ‘Zytase’ was 
relatively small38, and the author had a financial interest in the supplement. 
Therefore evidence is sparse and future research is needed in this area, 39 
especially as there is no scientific explanation why this effect should be found, 
nor is it known if those in the study were deficient in either zinc or phytase as 
suggested, such that the pool of zinc might have been sufficient without 
supplementation.  
  
Brand  
 
As can be seen in Table 1 almost all the research is based on trials of one brand, 
the end result of each is arguably only specific to that brand. This could be 
another variable on the longevity of effect in itself. Most of the research 
published has been carried out with editorial assistance or funding by one of the 
major pharmaceutical companies who produce the toxins. As such visibly 
unbiased discussion is lacking. The toxins are expensive, and a large scale trial, 
with all three of these licensed preparations would require significant funding.  
 
Despite heterogeneity between studies, those with direct comparisons suggest 
that AbobotulinumtoxinA (Allergan, Dysport – please refer to Figure 4) is 
superior to OnabotulinumtoxinA (Botox, Allergan), and IncobotulinumtoxinA 
(Bocouture, Merz) may be even better, as the remainder of the studies using this 
toxin find the results to be ongoing at the end of the study duration, so no end 
point can be clearly extrapolated. This is illustrated in Figure 3.  
 
 
Figure 5: Photograph of two of the brands commonly used in the UK.  
   
Skin type  
 
An earlier study comparing skin structure in females of 4 different ethnic groups 
found that the sub-epidermal non-echogenic band, which is less pronounced in 
African Americans, is a sensitive marker of skin ageing. OCT imagery was used to 
show that the thickness of the dermal–epidermal junction (DEJ) decreased with 
age, but remained higher in African Americans than in Caucasians, confirming 
that skin ageing is delayed in African Americans compared with all other ethnic 
populations. 40  
 
The best comparison among the studies would be between the studies by Dailey 
et al. (2009)22 and Grimes et al. (2009)32. Sample sizes are similar 18, 41 and both 
use 100% female patients, injected on 5 occasions with OnabotulinumtoxinA. 
Unfortunately the studies are heterogeneous, as the age ranges differed but the 
mean age was 43.722,. If we only compare the results where the same dose was 
used (20U), by 4 months, patients in the group with Fitzpatrick types V/VI were 
still 60% satisfied, but there were only approximately 10% with response at 
maximum frown, as rated by both the patient and the assessor. There was 
however no blinding in the latter of these two trials. Therefore although the 
results appear to suggest a better longevity of effect in the lighter skin tones this 
is likely to be because these studies had less robust control on the assessment, 
and methods across the studies were heterogeneous so they cannot be directly 
compared. In fact  
Kane et al. found duration of effect to be slightly greater in African American 
subjects29.  
Treatment repetition  
 
Dailey et al.22 state that it is conceivable that further wrinkle reduction may be 
achieved with a treatment regimen that extends beyond 20 months22, but there 
is paucity of data for treatments longer than 1 year. The study found that 
satisfaction improved with each treatment cycle, arguably those who were 
unsatisfied may be more likely to drop-out.  
 
 
Conclusion  
 
One of the most important points from the results is that there is no average 
duration of effect, as so many of the end points are beyond the end of the time 
allocated to the study. No less than 5 of the studies included in the literature 
review found the effects to be ongoing past the last patient follow-up. In one 
study longevity was found to be between 10-21 weeks, while another study 
estimated 3- 6 months longevity, which is arguably not precise enough to be very 
helpful to patients as a guide. The figures are so diverse that there is no simple 
advice that can be gleaned from it to inform patients. The effects may last 
between 2 and over 6 months. Furthermore the manner in which these results 
are measured may render these results inaccurate, as these studies reflect the 
perceived endpoint, and treatment intervals respectively, which are two 
different measures. Moreover, the majority of studies examined the duration of 
the effect of the toxin on Maximal Contraction not on wrinkle appearance at rest, 
which is in fact arguably the pertinent issue, as this is what most patients seeking 
glabellar treatment with toxin would want to achieve.  One factor that was less 
well assessed in studies was that of practitioner competence, as these studies 
were often single practitioners, and none were students or trainees. This is likely 
to be a hugely influential factor in the successful outcome and longevity of the 
treatment as it may influence dose, position of injection and also communication 
with the patient. 
 
 
Summary.  
 
In summary the current advice on longevity is flawed, as it is often based on the 
duration of loss of maximal contraction, and therefore not really describing the 
effect most patients probably seek. In review, having assessed what we know of 
how the different variables affect treatment duration it is possible to draw some 
conclusions and possible patient advice. The desirable duration of effect may 
differ according to its application. Advising not only on the duration, but 
understanding the factors that may influence this could be used to achieve the 
most desirable duration for any given case.  
 
Variable longevities of effect would be useful, as longer treatment durations 
reduce patient cost, and repeat visits, but shorter durations of effect may also be 
used to immobilise areas post-surgery. In the case of aesthetic treatments this 
could be a potential selling point for those patients who are unsure, and wish to 
‘try’ a treatment before they commit.  
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